Tenax Therapeutics to Participate in Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tenax Therapeutics (NASDAQ: TENX) will present at two investor conferences in early December 2025: a fireside chat at the 8th Annual Evercore Healthcare Conference on December 2, 2025 at 4:15 p.m. ET, and a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025 at 11:30 a.m. ET.
Participants include Chris Giordano, President & CEO, and Stuart Rich, M.D., Chief Medical Officer. Live and archived webcasts will be available from the company’s investor relations webpage.
Details
News Market Reaction – TENX
On Nov 25, the day this news came out, TENX closed 4.44% above the previous close.
Data tracked by StockTitan Argus for the Nov 25 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHAPEL HILL, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the following investor conferences:
8th Annual Evercore Healthcare Conference
Format: Fireside chat
Participants: Chris Giordano, President & Chief Executive Officer, Stuart Rich, M.D., Chief Medical Officer
Date and Time: December 2, 2025, at 4:15 p.m. ET
Piper Sandler 37th Annual Healthcare Conference
Format: Fireside chat
Participants: Chris Giordano, President & Chief Executive Officer, Stuart Rich, M.D., Chief Medical Officer
Date and Time: December 4, 2025, at 11:30 a.m. ET
The live and archived webcasts of the presentations will be accessible from the Company’s investor relations webpage.
About Tenax Therapeutics
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.
Contact:
Investor and Media:
Argot Partners
tenax@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.